Artbio emerges with $23M to make radioligand therapies for prostate cancer, with field still in 'early days'
Another startup is entering the radiopharma market, backed by F-Prime Capital and Omega Funds, with an experienced team from Novartis and Bayer.
Artbio is launching with $23 million and a pipeline of alpha radioligand therapies, including a PSMA-directed prostate cancer program. It’s an area of oncology targeted by others in the field, including Novartis’ Pluvicto — which ran into supply issues this winter — as well as the recently debuted Convergent Therapeutics.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.